Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
August 7th and 8th has a stacked schedule of events, not typical for AVXL. On Monday 8/7 we have the virtual gig and then on Tues 8/8 we have stock holders qtrly. rpt. Stay tuned I guess.
https://finance.yahoo.com/news/anavex-life-sciences-present-btig-113000382.html
So, all we must do is...PAY ATTENTION...THE SYSTEM (CNS) has a LOT TO SAY. We must stop thinking serially....
Anyone care to speculate on what will happen w/NAS and AVXL SP in particular on 8/3/2003? IMO, we did OK today in-spite of the going NAS melt down.
boi568
tredenwater2
Talon 38. Well done. Watch your 6.
Our competition with Biogen has been going on for years since the MS look.
8.45 +0.20 (+2.42%)
After hours: -...does this count?
TIA
Critical point here:
TempePhil...thx...excellent work.
AB-E-NORMAL...for AVXL...
Plexrec.... "well done"...
"Nuff Said"...The s1 receptor participates in the regulation of intracellular Ca2+ migration and maintains homeostasis and protects cognitive function damage [119,120]. Research on the role of the s1 receptor in mediating mitochondrial function has found that the s1 receptor attenuates hippocampal dendrite formation through scavenging of free radicals, and protects cells from damage by mitochondria-derived reactive oxygen species (ROS) [121,122,123]. The ER stress sensor inositol-requiring enzyme 1 (IRE1) facilitates mitochondrion-ER-nucleus signaling for cellular survival via the s1 receptor chaperone [75,124].[/quote]
https://www.mdpi.com/1422-0067/24/15/12025
Now, we need to hear from the RSD crew...bless the kids and families...helping to support WW sick people and to resolve little kids and their families pain...does not get much better...LETS ALL HAVE A GOOD WEEK FOR ONCE.
Thanks hnbbadger1...Noted no contradictions with AVXL research published to date.
[quote]Increasing evidence has proved that the s1 receptor holds great potential as a biomarker for early AD diagnosis and progression and the monitoring of AD drug efficacy [49]. Hallmarks of human AD include progressive cognitive decline that follows chronic neuroinflammation and the emergence of hyperphosphorylated tau protein aggregates and Aß plaques [46], with all playing critical and perhaps interrelated roles in the progression of AD. In particular, Ca2+ plays a critical role in learning and memory processes [114,115,116,117,118], and Ca2+ dyshomeostasis is a pathological feature of AD and other neurodegenerative diseases [114,115,116,117,118]. The s1 receptor forms a Ca2+-sensitive chaperone complex with the binding immunoglobulin protein/glucose-regulated protein 78 (BiP/GRP78), and prolongs Ca2+-signaling from ER into mitochondria by stabilizing inositol 1,4,5-trisphosphate receptor (IP3R) at the MAM [74]. The s1 receptor participates in the regulation of intracellular Ca2+ migration and maintains homeostasis and protects cognitive function damage [119,120]. Research on the role of the s1 receptor in mediating mitochondrial function has found that the s1 receptor attenuates hippocampal dendrite formation through scavenging of free radicals, and protects cells from damage by mitochondria-derived reactive oxygen species (ROS) [121,122,123]. The ER stress sensor inositol-requiring enzyme 1 (IRE1) facilitates mitochondrion-ER-nucleus signaling for cellular survival via the s1 receptor chaperone [75,124].[/quote]
https://www.mdpi.com/1422-0067/24/15/12025
Anyone else get a sense of comfort (just this side of warm-fuzzy) from last trading session -EOD results?
I like the little bounce we experienced and read it is driven by good news out there waiting. I do also hold out a positive attitude about other credible large Pharma co. having researched AVXL work/results/trials/direction .. .but that is just how I see the way work has been done by Dr.M and team. The AVXL staff-team have been around long enough to recognize the REAL thing when they see it.
My other observations are less positive or certain. I have begun to recognize just how devious/misleading the BP-WS processes are, having previous lab time on my own but never paying attention to just how many types of liars there are around BP/WS. Relying on process results is typically a safe bet for me but that all changed when I tried to get a rational line of thinking in support of FDA Amyloid closed minded status. It looks to me like the entire BP world has wrapped itself around the wrong flag pole and AVXL is not on that path at all. WGT, but it is a tough uphill slough. Anyways, my sense is we will see a breakout soon including AVXL proof by trials of RWD -RSD.
IMO, the other good news I see includes the (certain) avalanche-awakening to the CNS upstream work done by AVXL and the S1R AHAA moments including RSD-PDD-AD trial findings . This black hole cannot last indefinitely...one small lite is all we need...then...BBOOOM.
longtermbeliever:
hnbadger1: From MayoMobile’s interview on July 18 at AAIC-
“Dr. Grimmer thinks they're
being approached/in-convo with big pharma for
purchase/partnering which is why we have not
seen data yet.”
Makes sense, if true then some BP name gets in the photo-story when the biggest medical news ever is launched. An old Maine expression comes to mind..."Fish, or CUT BAIT". Doing nothing, is not an option.
tredenwater2...
Recommended reading: from sokol .... .Nice work....we got this.
Sokol,
Many thanks for this excellent compilation of AVXL trial data. Obviously the tools required to keep track of and analyze the findings for the CNS clinical world to deal with are badly needed.
All of this will make more sense some day, hopefully in our lifetimes.
If only the trials could get better synchronized then we could make better use of resources WW.
Danke.
bas2020
hnbadger1: Thank you for posting this well done AD paper. In fact it emphasizes what some of us have been saying here for a long time. That is, the FDA has done a poor job of being clear about Aymloid Plaque role as a cause for AD.
georgejjl...Any proof, PR, news from AVXL, other about this claim??Have not seen such claim posted ...
Thanks for the information.
IGNORE ...suggestion to all longs
plexrec
Excellent material here. New tool suite will/may actually add to CNS diseases overall scope/knowledge and complexity. BP is going to hate this. One Size does/may not fit all. AND, the social shoe horns in use must be shat-canned. IMO. Intelligence is a beautiful thing, even if it is artificial . We are all just @ the tip of beginning,, IMO.
HUH...https://alz-journals.onlinelibrary.wiley.com/toc/15525279/2023/19/S8
Retail AVXL holders need to rethink what ever (BUY/HOLD/SELL) price-time clocks you have running, IMO.
Anyone w/ some experience using/AI systems and the impact they may/might have on decisions would suggest the decision horizons can move as new reasoning-time lines become factors...(WAIT_SELL-BUY_ OTHER).
Expect that the new tools will likely introduce new variables and paths b/c their fields of data and decision factors . Some new variable paths may cause you to rethink what might have previously been/seemed obvious. One reaction may be that you will have new-more (what if ???) process questions to reason over than you typically do now.
It's all good, just stand back and rethink unintended possible consequences. This will be particularly true as the tool becomes more populated w/facts which you consider important but which you would have previously not even considered.
IMO, Dr.M. and staff may be spending a lot of time right now going through AI models-data being available and accuracy of data being used to reason over. Things/factors that previously (seemed) not have been in the decision pot may now show up w/various timelines attached. So, a quick obvious choice from the past may now take a lot longer, depending on data sources and the speed of the new AI system to respond to variables/questions.
bas2020
https://www.nytimes.com/2023/07/19/us/stanford-president-resigns-tessier-lavigne.html
Interesting Stanford U. findings. A key professor and AD academic leader has been determined to have been "at least" very sloppy in his area of responsibility ref AD reporting . Corruption and lies in academia are disappointing (to say the least). IMO, the AVXL WW team are much more insightful and valuable than we suspect they might be. We recognize that 50+ years is a long time to remain clueless as to AD cause. IMO, once we get the REAL-STORY (answer) many, many stories like this one will -may percolate to the surface, IMO. This should just NOT BE HAPPENING.
Any of us who have a sense that 50+ years of research in AD and still no solid published -proven proof of " root cause" ...HUH?? Dr. M is a low key guy, as he chooses . IMO< there is lot more of the same kind of academic outings in the future, once absolute proof of CNS diseases causes are proven. It may be that AVXL and AI methods and affiliations will be key to these future moments of truth.
Everyone...Keep the faith .
Nice Catch...
This guidance is what AVXL will/are providing. Anyone who has ever lead during systemic changes knows it is hard -time consuming painful work. Maybe that is why people avoid doing it. FDA process controls and disciplines are critical and required. The regulatory headset and making changes that work is tough to do, ask anyone who has ever had to do that.
IMO, that is what Dr.M. and his AVXL team are leading ...it's all about CHANGE ,it takes time. Sad to say.
Senge, P. (1990/2006). The fifth discipline: The art and practice of the learning organization. Doubleday.
] The fifth discipline: The art and practice of the learning organization
PM Senge
2006•books.google.com
Completely Updated and Revised This revised edition of Peter Senge’s bestselling classic, The Fifth Discipline, is based on fifteen years of experience in putting the book’s ideas into practice. As Senge makes clear, in the long run the only sustainable competitive advantage is your organization’s ability to learn faster than the competition. The leadership stories in the book demonstrate the many ways that the core ideas in The Fifth Discipline, many of which seemed radical when first published in 1990, have become deeply integrated into people’s ways of seeing the world and their managerial practices. In The Fifth Discipline, Senge describes how companies can rid themselves of the learning “disabilities” that threaten their productivity and success by adopting the strategies of learning organizations—ones in which new and expansive patterns of thinking are nurtured, collective aspiration is set free, and people are continually learning how to create results they truly desire. The updated and revised Currency edition of this business classic contains over one hundred pages of new material based on interviews with dozens of practitioners at companies like BP, Unilever, Intel, Ford, HP, Saudi Aramco, and organizations like Roca, Oxfam, and The World Bank. It features a new Foreword about the success Peter Senge has achieved with learning organizations since the book’s inception, as well as new chapters on Impetus (getting started), Strategies, Leaders’ New Work, Systems Citizens, and Frontiers for the Future. Mastering the disciplines Senge outlines in the book will:• Reignite the spark of genuine learning driven by people focused on what truly matters to them• Bridge teamwork into macro-creativity• Free you of confining assumptions and mindsets• Teach you to see the forest and the trees• End the struggle between work and personal time